Department of Psychiatry and Behavioral Science, Duke University Medical Center, Durham, North Carolina, USA.
J Clin Psychiatry. 2011 Jun;72(6):795-805. doi: 10.4088/JCP.10r06580.
To systematically review placebo-controlled randomized trials of homeopathy for psychiatric conditions.
Eligible studies were identified using the following databases from database inception to April 2010: PubMed, CINAHL, PsycINFO, Hom-Inform, Cochrane CENTRAL, National Center for Complementary and Alternative Medicine grantee publications database, and ClinicalTrials.gov. Gray literature was also searched using Google, Google Scholar, the European Committee for Homeopathy, inquiries with homeopathic experts and manufacturers, and the bibliographic lists of included published studies and reviews. Search terms were as follows: (homeopath* or homoeopath*) and (placebo or sham) and (anxiety or panic or phobia or post-traumatic stress or PTSD or obsessive-compulsive disorder or fear or depress* or dysthym* or attention deficit hyperactivity or premenstrual syndrome or premenstrual disorder or premenstrual dysphoric disorder or traumatic brain injury or fibromyalgia or chronic fatigue syndrome or myalgic encephalitis or insomnia or sleep disturbance). Searches included only English-language literature that reported randomized controlled trials in humans.
Trials were included if they met 7 criteria and were assessed for possible bias using the Scottish Intercollegiate Guidelines Network (SIGN) 50 guidelines. Overall assessments were made using the Grading of Recommendations Assessment, Development and Evaluation procedure. Identified studies were grouped into anxiety or stress, sleep or circadian rhythm complaints, premenstrual problems, attention-deficit/hyperactivity disorder, mild traumatic brain injury, and functional somatic syndromes.
Twenty-five eligible studies were identified from an initial pool of 1,431. Study quality according to SIGN 50 criteria varied, with 6 assessed as good, 9 as fair, and 10 as poor. Outcome was unrelated to SIGN quality. Effect size could be calculated in 16 studies, and number needed to treat, in 10 studies. Efficacy was found for the functional somatic syndromes group (fibromyalgia and chronic fatigue syndrome), but not for anxiety or stress. For other disorders, homeopathy produced mixed effects. No placebo-controlled studies of depression were identified. Meaningful safety data were lacking in the reports, but the superficial findings suggested good tolerability of homeopathy. A funnel plot in 13 studies did not support publication bias (χ(2)(1) = 1.923, P = .166).
The database on studies of homeopathy and placebo in psychiatry is very limited, but results do not preclude the possibility of some benefit.
系统评价针对精神科疾病的顺势疗法安慰剂对照随机试验。
从数据库建立至 2010 年 4 月,我们使用以下数据库确定了合格的研究:PubMed、CINAHL、PsycINFO、Hom-Inform、Cochrane 中心对照试验注册数据库、美国国立补充与替代医学中心资助出版物数据库和 ClinicalTrials.gov。还使用 Google、Google Scholar、欧洲顺势疗法委员会、向顺势疗法专家和制造商的咨询、纳入的已发表研究和综述的参考文献列表等方式搜索灰色文献。检索词如下:(homeopath或 homoeopath)和(placebo 或 sham)和(anxiety 或 panic 或 phobia 或 post-traumatic stress 或 PTSD 或 obsessive-compulsive disorder 或 fear 或 depress或 dysthym或 attention deficit hyperactivity 或 premenstrual syndrome 或 premenstrual disorder 或 premenstrual dysphoric disorder 或 traumatic brain injury 或 fibromyalgia 或 chronic fatigue syndrome 或 myalgic encephalitis 或 insomnia 或 sleep disturbance)。检索只包括报告人类随机对照试验的英文文献。
如果试验符合 7 项标准,并根据苏格兰校际指南网络( SIGN 50)50 项指南评估偏倚的可能性,则纳入试验。使用推荐评估、制定与评价分级程序进行总体评估。确定的研究分为焦虑或应激、睡眠或昼夜节律紊乱、经前问题、注意缺陷/多动障碍、轻度创伤性脑损伤和功能性躯体综合征。
从最初的 1431 项研究中,共确定了 25 项合格的研究。根据 SIGN 50 标准,研究质量差异较大,其中 6 项被评为良好,9 项为中等,10 项为较差。结果与 SIGN 质量无关。16 项研究可以计算疗效大小,10 项研究可以计算需要治疗的人数。功能性躯体综合征组(纤维肌痛和慢性疲劳综合征)疗效显著,但焦虑或应激组无效。对于其他疾病,顺势疗法产生了混合效应。未发现针对抑郁症的安慰剂对照研究。报告中缺乏有意义的安全性数据,但初步发现表明顺势疗法具有良好的耐受性。在 13 项研究中,漏斗图不支持发表偏倚(χ(2)(1)=1.923,P=.166)。
精神科顺势疗法和安慰剂研究的数据库非常有限,但结果并不排除一些益处的可能性。